UNSPSC 51311701: Meclizine or meclozine

This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C25H27ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L5TQ84570, chemically known as piperazine, 1- (p-chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)-, dihydrochloride but generally known as meclizine, which bears US NIH Compound Identifier 4034. European Medicines Agency schedules Meclozine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08685MIG.

The term MECLIZINE is an International Non-Proprietary Name. World Health Organization schedules meclizine in its Anatomical Therapeutic Chemical (ATC) Classification. Meclizine or meclozine bears US NLM identifiers UMLS ID C0025039 and NCI Concept Code C61610. SMILES: CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)CL.

UNSPSC 51311701 Meclizine or meclozine is a Commodity code that does not reflect what state and local governments are actually procuring under its classification. The recent solicitations tagged to this code center on naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals—none of which are meclizine-specific products. The code appears to be a mislabeling artifact in the available opportunity records, leaving no clear signal of actual meclizine demand in state and local procurement.

The three recent opportunities show activity spanning emergency response supplies (naloxone), health system pharmaceutical benefit strategy (Texas HHS direct-to-manufacturer initiative), and cooperative multi-state generic drug contracting (MMCAP), but none target the motion-sickness or nausea-relief medications that meclizine serves. Issuing bodies include Seminole County, Florida (IFB for naloxone and drug deactivation systems, due July 26, 2023), the Texas Health and Human Services Commission (RFI for direct prescription contracting, April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating states and local facilities including Oregon (RFP for generic and OTC products, due March 26, 2026). Without recent opportunities genuinely soliciting meclizine or meclozine products under this code, the activity and geographic concentration cannot be characterized from the source material.